CVS Health is facing new challenges, including its removal from the Horizon NJ Health Medicaid network due to a pricing dispute and increased scrutiny on Pharmacy Benefit Managers (PBMs) from the U.S. Department of Labor. These developments raise concerns about medication access and potential business impacts for CVS’s pharmacy and PBM operations. Despite these headwinds, CVS stock is currently trading around $76.33, with financial assessments suggesting it is undervalued, trading roughly 58% below its estimated fair value.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
CVS Faces Medicaid Network Loss And PBM Scrutiny As Valuation Looks Undemanding
CVS Health is facing new challenges, including its removal from the Horizon NJ Health Medicaid network due to a pricing dispute and increased scrutiny on Pharmacy Benefit Managers (PBMs) from the U.S. Department of Labor. These developments raise concerns about medication access and potential business impacts for CVS’s pharmacy and PBM operations. Despite these headwinds, CVS stock is currently trading around $76.33, with financial assessments suggesting it is undervalued, trading roughly 58% below its estimated fair value.